Arrowhead Pharmaceuticals Inc.

07/05/2022 | Press release | Distributed by Public on 07/05/2022 05:39

Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE